June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
October 2025 in “Frontiers in Medicine” Ixekizumab has known and some unexpected side effects.
3 citations
,
February 2024 in “Journal of the American Academy of Dermatology” Topical tofacitinib cream may help treat certain hair loss conditions with fewer risks.
January 2026 in “Food Science and Human Wellness” Flammulina velutipes polysaccharide helps the immune system fight tumors by activating certain pathways.
14 citations
,
October 2003 in “Annals of Oncology” About half the patients treated with capecitabine and docetaxel developed severe hand-foot syndrome.
Compound 6 is a promising candidate for better wound healing.
45 citations
,
January 2007 in “Journal of Clinical Oncology” Sorafenib may cause hand-foot and stump syndrome, requiring early detection and management.
6 citations
,
September 2024 in “Current Oncology” Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
49 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
September 2022 in “PubMed” Entadfi, a mix of finasteride and tadalafil, is used for BPH.
February 2026 in “International Journal of Nanomedicine” The system improved diabetic wound healing in rats.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
1 citations
,
August 2025 GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
May 2021 in “Letters in Applied NanoBioScience” Pranlukast and mirabegron may work as new diabetes drugs.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
January 2026 in “Quality in Sport” Semaglutide may help some skin disorders but can also cause skin issues.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
5 citations
,
September 2020 in “Proceedings - Baylor University. Medical Center” Tofacitinib successfully treated a woman's severe symptoms from a rare autoimmune condition.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
8 citations
,
May 2017 in “Singapore Medical Journal” A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
24 citations
,
July 2015 in “International Journal of Molecular Sciences” Fluoxetine may help reduce fat by limiting stem cell growth and fat cell formation.
April 2010 in “Nature Reviews Urology”
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
1 citations
,
October 2023 in “Journal of the Endocrine Society” Finasteride may worsen blood sugar control in diabetic patients.
April 2025 in “Frontiers in Pharmacology” Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
2 citations
,
August 2025 in “Scientific Reports” Pexidartinib often causes liver issues and fatigue, especially in women.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
4 citations
,
May 2019 in “Sultan Qaboos University Medical Journal” Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.
1 citations
,
January 2025 in “ARC Journal of Dermatology”